Cardiometabolic Disease Market Size, Share and Global Trend By Treatment (Angiotensin-converting Enzyme (ace) Inhibitors, Diuretics, Glucophage), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Regional Forecast, 2024-2032

The Cardiometabolic Disease can be described as a combination of metabolic dysfunctions which is often characterized by a number of diseases such as impaired glucose tolerance, insulin resistance, hypertension, central adiposity, and dyslipidemia. Individuals diagnosed with the cardiometabolic disease are two times more susceptible and three times more susceptible to die by coronary heart disease and heart attack or stroke respectively.

It can be further stated that cardiovascular disease is one of the many forms of the cardiometabolic disease. One of the critical reasons for the anticipation growth of the market is a very high prevalence of cardiometabolic disease and the other associated comorbidities such as diabetes, obesity amongst others. Due to the increasing initiatives towards the research & development of new cardiometabolic therapeutics and the increasing rate of obesity is also expected to further contribute to market growth. 

Cardiometabolic Disease and various associated comorbidities are amongst the most prevalent and common diseases globally due to a number of factors. Due to the increased awareness and the greater availability and access to cardiometabolic disease treatment options, some of the diseases are no longer fatal with efficient and appropriate treatment. This is further expected to contribute towards the growth of the market and the increased R&D for the new treatment options and the availability of the therapeutics in the emerging markets at subsidized prices are further expected to drive the market growth positively. 

The factor that is expected to inhibit the growth of the market is the adverse effects associated with cardiometabolic disease treatments. For instance, one of the most critical treatments for cardiometabolic diseases is the angiotensin-converting-enzyme (ACE) inhibitors, a group of drugs used for the treatment of heart failures and hypertension. But in some instances, the complications also include angioedema, a potentially fatal health condition. 

Key Players Covered 

Some of the major companies that are present in the global cardiometabolic disease market are Cardax, Inc., Novartis AG, Novo Nordisk A/S, Eli Lilly and Company, Bayer AG, Allergan, Boehringer Ingelheim International GmbH, AstraZeneca and other players. 

SEGMENTATION 

At present, ACE inhibitors account for the largest proportion of the market and this is expected to remain same during the forecast period because of the utilization of the treatment for the management of hypertension and heart failure. Also, there is a high prevalence of the disease in North America due to the high prevalence of comorbidities such as diabetes and obesity. 

Key Insights 

• Pipeline analysis
• Regulatory scenario by key countries
• Overview of therapeutics currently approved for the cardiometabolic disease
• Prevalence of cardiometabolic and cardiovascular disease by key countries
• New product launches 

Regional Analysis 

The global cardiometabolic disease market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for the cardiometabolic disease at present and they are expected to account for a large proportion of the market in the forecast period as well. In the U.S., according to the American College of Cardiology (ACC), there are an estimated 47 million individuals who are diagnosed with some form of the cardiometabolic disease, which can lead to the progression towards atherosclerosis disease. In the Asia Pacific region, China is expected to provide the largest market opportunity. This is owing to the high prevalence of cardiometabolic and cardiovascular disease in China. 

Key Industry Developments

• In March 2019, Alnylam Pharmaceuticals, Inc. announced that the company had submitted an application for the clinical trial authorization (CTA) to the U.K. regulatory authority for the initiation of a Phase 1 study for ALN-AGT, an investigational RNAi therapeutic for the targeting of angiotensinogen (AGT), for the treatment of hypertension and heart failure.
• In March 2019, Arrow Pharmaceuticals Inc., began the dosing of the first subjects in its Phase 1 clinical study of ARO-APOC3, a RNAi-based investigational medicine for the targeting of apolipoprotein C-III (apoC-III), to be utilised for the treatment of hypertriglyceridemia.